MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment to patients in need. Our lead candidate MBS8 is in phase I clinical trial with treatment of currently more then 45 patients at clinical sites in Denmark, Belgium and Spain.

MBS8 is a novel Lipid Nano Particle formulation with several unique selling points:

• Due to the Lipid Nano Particle (LNP) we have increased the Therapeutic Index by more than 20 fold
• Immune stimulating LNPs are engineered to reduce systemic cytokine production with a favourable safety profile
• Administration by IV infusion is a major advantage for doctors and patients to minimize complications
• MBS8 is an LNP incorporating a small molecule TLR7 NCE agonist
• MBS8 show superior anti-tumor activity in preclinical models compared to many approved treatments
• Synergy with Immune Checkpoint Inhibitors, radiotherapy and chemotherapy with complete remission in preclinical models